Claravis

Claravis is a pharmaceutical entity primarily known for its eponymous product, a generic version of isotretinoin used in the treatment of severe recalcitrant nodular acne. Originally developed and marketed by Barr Laboratories, the Claravis brand and its associated manufacturing operations became part of Teva Pharmaceuticals following Teva's acquisition of Barr in 2008. The company operates as a subsidiary within the Teva portfolio, focusing on the commercialization and distribution of this high-potency retinoid therapy. Claravis is subject to the iPLEDGE risk evaluation and mitigation strategy (REMS) due to the significant teratogenic risks associated with isotretinoin. Its business model is centered on providing a cost-effective generic alternative to the original brand-name drug, Accutane.